Clinical trials: Prostate Cancer Recurrent
Prostate Cancer, Cancer Recurrence
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
- Trial name
- PERYTON (NCT04642027)
- Testing
- Conventional sEBRT, Hypofractionated sEBRT
- Where
- 13 sites in Netherlands
- Volunteers
- 538 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer
Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00242931
- Testing
- Nonmyeloablative stem cell conditioning regimen
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Recurrent Adenocarcinoma
Jump: MR Simulation For Radiation Therapy Master Protocol
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
- Conditions
- Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
- Trial name
- JUMP (NCT04545957)
- Testing
- MRI Simulator, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Brigham and Women's Hospital
Bladder Cancer
Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression
The purpose of this study is to compare medical and surgical treatments of benign prostate hyperplasia in patients who have non muscle invasive bladder cancer for tumour recurrence and progression.
- Trial name
- NCT02443844
- Testing
- Transurethral Resection, Tamsulosin
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Diskapi Teaching and Research Hospital
Prostate Cancer
Ga-68 PSMA-11 PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: Digital PET/CT Versus Analog PET/CT
Ga-68 PSMA-11 PET/CT is known as useful method for localizing recurred tumor lesions in prostate cancer patients with biochemical recurrence [elevated serum prostate specific antigen (PSA) after radical prostatectomy].
- Trial name
- NCT04846894
- Testing
- Ga-68 PSMA-11 PET/CT imaging
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Jin-Sook Ryu
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752. In Part A of the study, the preliminary maximum tolerated dose (MTD) of the drug combinations will be found by giving sequentially higher…
- Trial name
- NCT01295632
- Testing
- ridaforolimus, MK-0752, MK-2206
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Biochemically Recurrent Prostate Cancer
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy…
- Trial name
- ARASTEP (NCT05794906)
- Testing
- Darolutamide (BAY1841788, Nubeqa), ADT
- Where
- 226 sites in United States, Australia and 21 more
- Volunteers
- 985 people
- Sponsor
- Bayer
Prostate Cancer
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA…
- Trial name
- NCT03768349
- Testing
- Ga-68 PSMA11, F-18 PSMA 1007
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006114
- Testing
- mitoxantrone hydrochloride, vinorelbine tartrate
- Where
- 10 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Prostate Cancer
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00898833
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 868 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
This study is open to men who have biochemical recurrence (BCR, increased PSA) following local treatment of their prostate cancer.
- Trial name
- NCT02811809
- Testing
- Apalutamide, IHT
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Prostate Cancer
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005857
- Testing
- trastuzumab, docetaxel
- Where
- 4 sites in United States
- Sponsor
- City of Hope Medical Center
Localised Prostate Cancer, Locally Advanced Prostate Cancer
MRI Guided Transurethral HIFU for Various Prostate Diseases
This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD).
- Conditions
- Localised Prostate Cancer, Locally Advanced Prostate Cancer, Locally Recurrent Prostate Cancer, Benign Prostatic Hyperplasia
- Trial name
- HIFU-PRO (NCT03350529)
- Testing
- MRI guided transurethral HIFU ablation of prostatic tissue
- Where
- Finland
- Volunteers
- 87 people
- Sponsor
- Turku University Hospital
Recurrent Prostate Cancer, Stage I Prostate Cancer
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after…
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00103194
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
This prospective pilot study will assess the feasibility of rh PSMA 7.3 positron emission tomography/magnetic resonance imaging (PET/MRI) scans in detecting prostate cancer that may have come back (recurrent) in patients with…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT04978675
- Testing
- Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen
RATIONALE: Eating a diet high in soy foods may lower the risk of some types of cancer. Isoflavones are compounds found in soy food that may prevent cancer.
- Trial name
- NCT01682941
- Testing
- Arm I Soy Bread, Arm II Soy-Almond Bread
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
This phase II trial is studying how well vorinostat works in treating patients with progressive metastatic prostate cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00330161
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)